Perlegen Sciences Inc. entered a four-year research collaboration with Pfizer Inc for whole genome and replication studies that may identify genes associated with major diseases and predict patient responses to certain medicines.

Researchers from both companies will conduct whole genome studies involving DNA samples from clinical trials. Pfizer and Perlegen scientists will design the research and analyse the results. Perlegen will conduct the genotyping, reading of the DNA, in the individual samples, using Affymetrix GeneChip technology, claims a company release.

Under the terms of the agreement, Perlegen and Pfizer will share in certain intellectual property rights resulting from the collaboration. Pfizer will provide research payments to Perlegen.

"We are excited to continue our collaboration with the outstanding scientific team at Pfizer Inc. We hope the results of our genetic research together will lead to improved health care for patients," said Paul J. Cusenza, senior vice president of Perlegen Sciences.

David R. Cox, chief scientific officer of Perlegen Sciences said, "By combining the scientific strengths of Perlegen and Pfizer, we greatly improve the prospect of positively impacting a number of presently unmet medical needs."

Perlegen Sciences Inc. analyses millions of genetic variations in DNA samples obtained from clinical trial participants. This information is used to explain and predict the efficacy and adverse effect profiles of prescription drugs.